VOLIBUS 0.2 (Voglibose (0.2mg))

VOLIBUS 0.2 Tablet is indicated for the management of type 2 diabetes mellitus, aiding in the regulation of elevated blood glucose levels that occur after meals. This medication is typically prescribed when dietary modifications and other diabetes medications have failed to sufficiently control hyperglycemia. It is essential to take VOLIBUS 0.2 shortly before eating, and the prescribing physician will determine the appropriate dosage and frequency of administration to optimize blood sugar control. Abrupt discontinuation without medical advice could lead to an increase in blood glucose levels, heightening the risk of severe complications such as kidney damage or vision impairment. This medication is intended to be part of a comprehensive treatment plan that includes adherence to a nutritious diet, regular physical activity, and weight management as recommended by healthcare professionals. Patients are encouraged to consistently monitor their blood sugar levels during treatment. While VOLIBUS 0.2 can lead to certain gastrointestinal side effects, it is important to note that this medication alone does not typically cause hypoglycemia; however, when combined with other diabetes treatments, particularly insulin or sulfonylureas, the risk of low blood sugar may increase. Patients should be aware that hypoglycemia should be managed with glucose intake, as standard table sugar may not be effective in reversing low blood sugar levels in those receiving this medication. Prior to starting treatment, it is crucial to inform your healthcare provider of any existing kidney or liver issues. Patients with bowel inflammation or ulceration, such as ulcerative colitis or Crohn’s disease, should avoid this medication. Pregnant and nursing mothers should seek medical advice before using VOLIBUS 0.2. A complete list of concurrent medications should also be shared with the healthcare professional to ensure safety while on this treatment.